-
Mashup Score: 2The Leukemia & Lymphoma Society 2025 Research Grants Include Acute Leukemia in Children with Down Syndrome | Leukemia and Lymphoma Society - 15 day(s) ago
The Leukemia & Lymphoma Society 2025 Research Grants Include Acute Leukemia in Children with Down Syndrome > Page Components
Source: www.lls.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 9Gut microbiota modulation to prevent progression of smoldering multiple myeloma to active disease | Leukemia and Lymphoma Society - 16 day(s) ago
Blocking the progression of smoldering multiple myeloma (SMM) to active MM is an unmet clinical need. In primary mouse models of MM, we aim at demonstrating that modulation of the gut microbiota by vaccination against the commensal Prevotella heparinolytica and/or colonization by P. melaninogenica, also in combination with anti-PD-L1 antibodies, inhibit the progression of asymptomatic MM to full-blown disease. Our findings are expected to provide the ground for clinical trials in SMM patients.
Source: www.lls.orgCategories: General Medicine News, Partners & KOLsTweet-
Gut health and multiple myeloma—is there a connection? 🧬 Research led by Matteo Bellone, MD, from @SanRaffaeleMI and funded by LLS, will be presented today at #ASH24 at 5:30 pm PT. Learn more now 👉 https://t.co/GBllHpPziq @ASH_hematology https://t.co/Ez2kuOq6sp
-
-
Mashup Score: 3The Leukemia & Lymphoma Society (LLS) Data at ASH Provides Glimpse into the Future of Blood Cancer Treatment | Leukemia and Lymphoma Society - 16 day(s) ago
The Leukemia & Lymphoma Society (LLS) Data at ASH Provides Glimpse into the Future of Blood Cancer Treatment > Page Components
Source: www.lls.orgCategories: General Medicine News, Partners & KOLsTweet-
Learn more by checking out their findings here: https://t.co/uorfiZtiaV
-
-
Mashup Score: 30Annual Report 2024 | Leukemia and Lymphoma Society - 23 day(s) ago
Annual Report 2024 > Page Components
Source: www.lls.orgCategories: General Medicine News, Partners & KOLsTweet-
Bold moves, big impact. For 75 years, we’ve been united in action, and 2024 was no exception. ❤️ Thanks to your generosity, we’re moving closer to a world without #BloodCancer. 🌍 See the milestones YOU made possible in our annual report 👉 https://t.co/3qKwZDomC8 https://t.co/iaU1DR7ZDl
-
-
Mashup Score: 9Advancements in Aggressive Non-Hodgkin Lymphomas (NHL) | Leukemia and Lymphoma Society - 1 month(s) ago
Join us for a free webinar covering the latest information for patients and caregivers. To register by phone, call (877) 264-4949. Topics Covered We invite you to learn more about: How your NHL subtype determines treatment goals and strategies Current and emerging therapies for aggressive subtypes of NHL Methods to manage side effects The importance of discussing quality-of-life issues with your healthcare team Speaker Joshua Brody, MD Director, Lymphoma Immunotherapy Program Icahn School of Medicine at Mount Sinai Hess Center for Science and Medicine New York, NY Submit a question for Dr. Brody to answer during the Q&A session. Program Support Support for this program provided by Genentech, a member of the Roche Group. < Back to Webcasts
Source: www.lls.orgCategories: General Medicine News, Partners & KOLsTweet-
How is the landscape of #lymphoma treatment evolving? Get an inside look at new developments in aggressive non-Hodgkin lymphomas in our upcoming webcast with @JoshuaBrodyMD from @IcahnMountSinai. Secure your spot 👉 https://t.co/XdGC3wLPqY #lymsm https://t.co/VQHwjGBbWS
-
-
Mashup Score: 15Targeting Microenvironment Determinants in Peripheral T-cell Lymphoma | Leukemia and Lymphoma Society - 1 month(s) ago
Peripheral T-cell lymphomas are highly aggressive blood cancer that have very poor survival rate, highlighting the need for new therapies to improve patient survival. We aim to improve our understanding of the characteristics of the individual cancer cells and their interaction with surrounding cells in the tumor environment with the goal of identifying new drugs that we can validate in preclinical models and move into more efficient treatments for lymphoma patients.
Source: www.lls.orgCategories: General Medicine News, Partners & KOLsTweet-
From the lab to potential lifesaving therapies—Dr. @teresa_palomero is on a mission to transform how we understand and treat Peripheral T-cell lymphomas (PTCL). 🔬🧬 Her work could be a game-changer for patients facing this aggressive cancer. Learn more 👉 https://t.co/DRduckCZOI… https://t.co/lYvDywZ0d4 https://t.co/Xn5llpR3Gf
-
-
Mashup Score: 1Myelodysplastic Syndromes | Symptoms, Treatments, FAQs | LLS - 2 month(s) ago
Myelodysplastic Syndromes are a group of diseases that affect the blood and marrow. Learn more about the development of MDS, possible risk factors.
Source: www.lls.orgCategories: General Medicine News, Partners & KOLsTweet-
To learn more about this blood cancer 👉 https://t.co/DfC5tPZstU https://t.co/g4oP40jMdg
-
-
Mashup Score: 2
Protecting Patients from Junk Insurance > Page Components
Source: www.lls.orgCategories: General Medicine News, Onc News and JournalsTweet-
Junk insurance policies: they’re just tricks, with no treats. That’s why Americans on ALL sides of the aisle agree that they should be required to follow the same rules as traditional insurance. Learn more: https://t.co/MJb90xNRox #NoJunkPlans https://t.co/ebBSLddXDz
-
-
Mashup Score: 0
LLS Scholarship for Blood Cancer Survivors > Page Components
Source: www.lls.orgCategories: General Medicine News, Partners & KOLsTweet-
Help us support even more survivors through The LLS Scholarship for Blood Cancer Survivors, offering up to $7,500 for blood cancer survivors pursuing vocational, trade, two-year, or four-year undergraduate education. Learn more or apply today here 👉 https://t.co/aWjI1262ZH… https://t.co/2KAgrh6khC
-
-
Mashup Score: 10Targeting the microenvironment to increase immunity and immunotherapy response in DLBCL | Leukemia and Lymphoma Society - 2 month(s) ago
To survive and proliferate lymphoma cells must co-opt normal cells residing the tumor microenvironment. This process results in the suppression of the activity of immune cells that otherwise will attack cancer cells. In this project we will develop a novel oral treatment that by acting on the microenvironment will restore lymphoma immunity and increase the activity of immunotherapy.
Source: www.lls.orgCategories: General Medicine News, Partners & KOLsTweet-
Meet @LCerchietti, MD! 🔬🧬 We’re proud to support Dr. Cerchietti’s research to help the immune system fight aggressive blood cancers like diffuse large B-cell lymphoma (DLBCL) with innovative treatments. Learn more 👉 https://t.co/2kxS9GUHxx #lymsm https://t.co/xgQnWozrjI
-
Learn more about the latest research we’re funding 👉 https://t.co/2T7sKCJtEA (3/3) #ASH24